BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

516 related articles for article (PubMed ID: 21544726)

  • 1. Effects of quercetin on the bioavailability of doxorubicin in rats: role of CYP3A4 and P-gp inhibition by quercetin.
    Choi JS; Piao YJ; Kang KW
    Arch Pharm Res; 2011 Apr; 34(4):607-13. PubMed ID: 21544726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of myricetin on the bioavailability of doxorubicin for oral drug delivery in rats: possible role of CYP3A4 and P-glycoprotein inhibition by myricetin.
    Choi SJ; Shin SC; Choi JS
    Arch Pharm Res; 2011 Feb; 34(2):309-15. PubMed ID: 21380815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of the antioxidant baicalein on the pharmacokinetics of nimodipine in rats: a possible role of P-glycoprotein and CYP3A4 inhibition by baicalein.
    Cho YA; Choi JS; Burm JP
    Pharmacol Rep; 2011; 63(4):1066-73. PubMed ID: 22001996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of oral curcumin on the pharmacokinetics of intravenous and oral etoposide in rats: possible role of intestinal CYP3A and P-gp inhibition by curcumin.
    Lee CK; Ki SH; Choi JS
    Biopharm Drug Dispos; 2011 May; 32(4):245-51. PubMed ID: 21506134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of simvastatin on the pharmacokinetics of diltiazem and its main metabolite, desacetyldiltiazem, after oral and intravenous administration in rats: possible role of P-glycoprotein and CYP3A4 inhibition by simvastatin.
    Choi DH; Choi JS; Li C; Choi JS
    Pharmacol Rep; 2011; 63(6):1574-82. PubMed ID: 22358108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of curcumin on the pharmacokinetics of tamoxifen and its active metabolite, 4-hydroxytamoxifen, in rats: possible role of CYP3A4 and P-glycoprotein inhibition by curcumin.
    Cho YA; Lee W; Choi JS
    Pharmazie; 2012 Feb; 67(2):124-30. PubMed ID: 22512082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of nifedipine on the pharmacokinetics of repaglinide in rats: possible role of CYP3A4 and P-glycoprotein inhibition by nifedipine.
    Choi JS; Choi I; Choi DH
    Pharmacol Rep; 2013; 65(5):1422-30. PubMed ID: 24399740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of lovastatin on the pharmacokinetics of diltiazem and its main metabolite, desacetyldiltiazem, in rats: possible role of cytochrome P450 3A4 and P-glycoprotein inhibition by lovastatin.
    Hong SP; Yang JS; Han JY; Ha SI; Chung JW; Koh YY; Chang KS; Choi DH
    J Pharm Pharmacol; 2011 Jan; 63(1):129-35. PubMed ID: 21189658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of baicalein, an antioxidant, on the bioavailability of doxorubicin in rats: possible role of P-glycoprotein inhibition by baicalein.
    Shin SC; Li C; Choi JS
    Pharmazie; 2009 Sep; 64(9):579-83. PubMed ID: 19827298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of efonidipine on the pharmacokinetics and pharmacodynamics of repaglinide: possible role of CYP3A4 and P-glycoprotein inhibition by efonidipine.
    Li C; Choi DH; Choi JS
    J Pharmacokinet Pharmacodyn; 2012 Feb; 39(1):99-108. PubMed ID: 22210483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of kaempferol to increase bioavailability and pharmacokinetics of nifedipine in rats.
    Park JW; Choi JS
    Chin J Nat Med; 2019 Sep; 17(9):690-697. PubMed ID: 31526504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of pioglitazone on the pharmacokinetics of nifedipine and its main metabolite, dehydronifedipine, in rats.
    Choi JS; Choi I; Choi DH
    Eur J Drug Metab Pharmacokinet; 2016 Jun; 41(3):231-8. PubMed ID: 25549928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of nifedipine in rats: Possible role of P-gp and CYP3A4 inhibition by HMG-CoA reductase inhibitors.
    Lee CK; Choi JS; Choi DH
    Pharmacol Rep; 2015 Feb; 67(1):44-51. PubMed ID: 25560574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel.
    Hendrikx JJ; Lagas JS; Rosing H; Schellens JH; Beijnen JH; Schinkel AH
    Int J Cancer; 2013 May; 132(10):2439-47. PubMed ID: 23090875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of quercetin on the pharmacokinetics of Etoposide after oral or intravenous administration of etoposide in rats.
    Li X; Choi JS
    Anticancer Res; 2009 Apr; 29(4):1411-5. PubMed ID: 19414395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of silibinin, inhibitor of CYP3A4 and P-glycoprotein in vitro, on the pharmacokinetics of paclitaxel after oral and intravenous administration in rats.
    Lee CK; Choi JS
    Pharmacology; 2010; 85(6):350-6. PubMed ID: 20523105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced bioavailability of tamoxifen after oral administration of tamoxifen with quercetin in rats.
    Shin SC; Choi JS; Li X
    Int J Pharm; 2006 Apr; 313(1-2):144-9. PubMed ID: 16516418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of losartan and its main metabolite EXP-3174 in rats: possible role of CYP3A4 and P-gp inhibition by HMG-CoA reductase inhibitors.
    Yang SH; Choi JS; Choi DH
    Pharmacology; 2011; 88(1-2):1-9. PubMed ID: 21709429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quercetin significantly decreased cyclosporin oral bioavailability in pigs and rats.
    Hsiu SL; Hou YC; Wang YH; Tsao CW; Su SF; Chao PD
    Life Sci; 2002 Dec; 72(3):227-35. PubMed ID: 12427482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of licochalcon A on the pharmacokinetics of losartan and its active metabolite, EXP-3174, in rats.
    Choi JS; Choi JS; Choi DH
    Pharmazie; 2013 Nov; 68(11):882-8. PubMed ID: 24380237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.